Clinical trials
Completed Phase 1/2 trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
121 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 9 |
| 2009 | 13 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 7 |
| 2016 | 9 |
| 2017 | 3 |
| 2018 | 8 |
| 2019 | 4 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 121 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Swiss Cancer Institute | 11 |
| Bristol-Myers Squibb | 8 |
| University Hospital, Basel, Switzerland | 8 |
| University of Zurich | 8 |
| Novartis Pharmaceuticals | 7 |
| Merck Sharp & Dohme LLC | 5 |
| University Hospital, Geneva | 5 |
| Pfizer | 4 |
| Basilea Pharmaceutica | 3 |
| Cytos Biotechnology AG | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Melanoma | 12 |
| Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Breast Neoplasms | 6 |
| Glioblastoma | 6 |
| Colorectal Neoplasms | 5 |
| Ovarian Neoplasms | 5 |
| Colonic Neoplasms | 4 |
| Leukemia, Myeloid, Acute | 4 |
| Rectal Neoplasms | 4 |
Trials
Showing 1 to 25 of 121. Each trial links to its page on Pharma Observatory.
21 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.